Compare · GILD vs MGX
GILD vs MGX
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Metagenomi Therapeutics Inc. (MGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and MGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $169.21B, about 3143.0x MGX ($53.8M).
- Over the past year, GILD is up 37.8% and MGX is down 0.7% - GILD leads by 38.5 points.
- GILD has been more active in the news (18 items in the past 4 weeks vs 3 for MGX).
- GILD has more recent analyst coverage (25 ratings vs 8 for MGX).
- Company
- Gilead Sciences Inc.
- Metagenomi Therapeutics Inc.
- Price
- $136.25+2.05%
- $1.44+2.86%
- Market cap
- $169.21B
- $53.8M
- 1M return
- -1.87%
- +5.49%
- 1Y return
- +37.78%
- -0.69%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2024
- News (4w)
- 18
- 3
- Recent ratings
- 25
- 8
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Director Bluestone Jeffrey was granted 1,146 shares, increasing direct ownership by 13% to 10,066 units (SEC Form 4)
- Director Barton Jacqueline K was granted 1,146 shares, increasing direct ownership by 4% to 27,202 units (SEC Form 4)
- Director Horning Sandra was granted 1,146 shares, increasing direct ownership by 22% to 6,293 units (SEC Form 4)
- Director Love Ted W was granted 1,146 shares, increasing direct ownership by 26% to 5,484 units (SEC Form 4)
- Director Rodriguez Javier was granted 1,146 shares, increasing direct ownership by 9% to 13,364 units (SEC Form 4)
- Director Welters Anthony was granted 1,146 shares, increasing direct ownership by 10% to 12,894 units (SEC Form 4)
- Director Manwani Harish was granted 1,146 shares and covered exercise/tax liability with 224 shares, increasing direct ownership by 7% to 15,015 units (SEC Form 4)
- SEC Form 4 filed by Director Kramer Kelly A.
- Gilead Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
Latest MGX
- SEC Form DEFA14A filed by Metagenomi Therapeutics Inc.
- SEC Form DEF 14A filed by Metagenomi Therapeutics Inc.
- Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
- SEC Form 4 filed by Irish Jian
- SEC Form 4 filed by Wein Matthew
- SEC Form 4 filed by Wapnick Pamela
- Chief Financial Officer Wapnick Pamela sold $2,530 worth of shares (1,581 units at $1.60), decreasing direct ownership by 0.84% to 187,375 units (SEC Form 4)
- Officer Wein Matthew sold $771 worth of shares (482 units at $1.60), decreasing direct ownership by 0.42% to 114,549 units (SEC Form 4)
- Chief Executive Officer Irish Jian gifted 228,462 shares and sold $2,571 worth of shares (1,607 units at $1.60), decreasing direct ownership by 41% to 333,770 units (SEC Form 4)
- SEC Form S-8 filed by Metagenomi Therapeutics Inc.